Nanoliposomes As Nonviral Vectors in Cancer Gene Therapy

Overview

Journal MedComm (2020)

Specialty Health Services

Date 2024 Jun 26

PMID 38919334

Authors

Safiye Nur Yildiz

Maliheh Entezari

Mahshid Deldar Abad Paskeh

Sepideh Mirzaei

Alireza Kalbasi

Amirhossein Zabolian

Farid Hashemi

Kiavash Hushmandi

Mehrdad Hashemi

Mehdi Raei

Mohammad Ali Sheikh Beig Goharrizi

Amir Reza Aref

Ali Zarrabi

Jun Ren

Gorka Orive

Navid Rabiee

Yavuz Nuri Ertas

Affiliations

Soon will be listed here.

Abstract

Nonviral vectors, such as liposomes, offer potential for targeted gene delivery in cancer therapy. Liposomes, composed of phospholipid vesicles, have demonstrated efficacy as nanocarriers for genetic tools, addressing the limitations of off-targeting and degradation commonly associated with traditional gene therapy approaches. Due to their biocompatibility, stability, and tunable physicochemical properties, they offer potential in overcoming the challenges associated with gene therapy, such as low transfection efficiency and poor stability in biological fluids. Despite these advancements, there remains a gap in understanding the optimal utilization of nanoliposomes for enhanced gene delivery in cancer treatment. This review delves into the present state of nanoliposomes as carriers for genetic tools in cancer therapy, sheds light on their potential to safeguard genetic payloads and facilitate cell internalization alongside the evolution of smart nanocarriers for targeted delivery. The challenges linked to their biocompatibility and the factors that restrict their effectiveness in gene delivery are also discussed along with exploring the potential of nanoliposomes in cancer gene therapy strategies by analyzing recent advancements and offering future directions.

Citing Articles

Research Progress of Phospholipid Vesicles in Biological Field.

Zhang N, Song J, Han Y Biomolecules. 2025; 14(12.

PMID: 39766335 PMC: 11726895. DOI: 10.3390/biom14121628.

Nanoliposomes as nonviral vectors in cancer gene therapy.

Yildiz S, Entezari M, Paskeh M, Mirzaei S, Kalbasi A, Zabolian A MedComm (2020). 2024; 5(7):e583.

PMID: 38919334 PMC: 11199024. DOI: 10.1002/mco2.583.

References

Yang Z, Li J, Wang Z, Dong D, Qi X . Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 2014; 35(19):5226-39. DOI: 10.1016/j.biomaterials.2014.03.017. View

Shanmugam M, Warrier S, Kumar A, Sethi G, Arfuso F . Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer. Curr Vasc Pharmacol. 2017; 15(6):503-519. DOI: 10.2174/1570161115666170713094319. View

Yang Q, Lai S . Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015; 7(5):655-77. PMC: 4515207. DOI: 10.1002/wnan.1339. View

Zhen S, Takahashi Y, Narita S, Yang Y, Li X . Targeted delivery of CRISPR/Cas9 to prostate cancer by modified gRNA using a flexible aptamer-cationic liposome. Oncotarget. 2016; 8(6):9375-9387. PMC: 5354738. DOI: 10.18632/oncotarget.14072. View

Li X, Zhang L, Yu L, Wei W, Lin X, Hou X . shRNA-mediated AMBRA1 knockdown reduces the cisplatin-induced autophagy and sensitizes ovarian cancer cells to cisplatin. J Toxicol Sci. 2016; 41(1):45-53. DOI: 10.2131/jts.41.45. View

Xie X, Yang Y, Yang Y, Mei X . Photolabile-caged peptide-conjugated liposomes for siRNA delivery. J Drug Target. 2015; 23(9):789-99. DOI: 10.3109/1061186X.2015.1009077. View

Hobel S, Aigner A . Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013; 5(5):484-501. DOI: 10.1002/wnan.1228. View

Li W, Yan R, Liu Y, He C, Zhang X, Lu Y . Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid and . Drug Deliv. 2019; 26(1):794-802. PMC: 6711155. DOI: 10.1080/10717544.2019.1645244. View

Wang P, Yu N, Wang Y, Sun H, Yang Z, Zhou S . Co-delivery of PLK1-specific shRNA and doxorubicin via core-crosslinked pH-sensitive and redox ultra-sensitive micelles for glioma therapy. J Mater Chem B. 2020; 6(1):112-124. DOI: 10.1039/c7tb02160g. View

10.

Shermane Lim Y, Xiang X, Garg M, Le M, Wong A, Wang L . The double-edged sword of H19 lncRNA: Insights into cancer therapy. Cancer Lett. 2020; 500:253-262. DOI: 10.1016/j.canlet.2020.11.006. View

11.

Pattipeiluhu R, Crielaard S, Klein-Schiphorst I, Florea B, Kros A, Campbell F . Unbiased Identification of the Liposome Protein Corona using Photoaffinity-based Chemoproteomics. ACS Cent Sci. 2020; 6(4):535-545. PMC: 7181318. DOI: 10.1021/acscentsci.9b01222. View

12.

Yang D, Li Y, Qi Y, Chen Y, Yang X, Li Y . Delivery of siRNA Using Cationic Liposomes Incorporating Stearic Acid-modified Octa-Arginine. Anticancer Res. 2016; 36(7):3271-6. View

13.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

14.

Levine R, Dinh C, Harris M, Kokkoli E . Targeting HPV-infected cervical cancer cells with PEGylated liposomes encapsulating siRNA and the role of siRNA complexation with polyethylenimine. Bioeng Transl Med. 2018; 1(2):168-180. PMC: 5675078. DOI: 10.1002/btm2.10022. View

15.

Kang Y, Lu L, Lan J, Ding Y, Yang J, Zhang Y . Redox-responsive polymeric micelles formed by conjugating gambogic acid with bioreducible poly(amido amine)s for the co-delivery of docetaxel and MMP-9 shRNA. Acta Biomater. 2017; 68:137-153. DOI: 10.1016/j.actbio.2017.12.028. View

16.

Almajidi Y, Kadhim M, Alsaikhan F, Turki Jalil A, Sayyid N, Ramirez-Coronel A . Doxorubicin-loaded micelles in tumor cell-specific chemotherapy. Environ Res. 2023; 227:115722. DOI: 10.1016/j.envres.2023.115722. View

17.

Zhang L, Liu S, Liu H, Yang C, Jiang A, Wei H . Versatile cationic liposomes for RIP3 overexpression in colon cancer therapy and RIP3 downregulation in acute pancreatitis therapy. J Drug Target. 2019; 28(6):627-642. DOI: 10.1080/1061186X.2019.1708370. View

18.

Cheng J, Wang L, Wang H, Tang F, Cai W, Sethi G . Insights into Biological Role of LncRNAs in Epithelial-Mesenchymal Transition. Cells. 2019; 8(10). PMC: 6829226. DOI: 10.3390/cells8101178. View

19.

Xu B, Mei J, Ji W, Bian Z, Jiao J, Sun J . LncRNA SNHG3, a potential oncogene in human cancers. Cancer Cell Int. 2020; 20(1):536. PMC: 7640707. DOI: 10.1186/s12935-020-01608-x. View

20.

Sakamoto J, van de Ven A, Godin B, Blanco E, Serda R, Grattoni A . Enabling individualized therapy through nanotechnology. Pharmacol Res. 2010; 62(2):57-89. PMC: 2886806. DOI: 10.1016/j.phrs.2009.12.011. View